دورية أكاديمية
Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results
| العنوان: | Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results |
|---|---|
| المؤلفون: | Palmerini, Emanuela, Ruggieri, Pietro, Angelini, Andrea, Boriani, Stefano, Campanacci, Domenico, Milano, Giuseppe M., Cesari, Marilena, Paioli, Anna, Longhi, Alessandra, Abate, Massimo E., Scoccianti, Guido, Terzi, Silvia, Trovarelli, Giulia, Franchi, Alessandro, Picci, Piero, Ferrari, Stefano, Leopardi, Martina Piccinni, Pierini, Michela |
| المساهمون: | Palmerini, Emanuela, Ruggieri, Pietro, Angelini, Andrea, Boriani, Stefano, Campanacci, Domenico, Milano, Giuseppe M., Cesari, Marilena, Paioli, Anna, Longhi, Alessandra, Abate, Massimo E., Scoccianti, Guido, Terzi, Silvia, Trovarelli, Giulia, Franchi, Alessandro, Picci, Piero, Ferrari, Stefano, Leopardi, Martina Piccinni, Pierini, Michela |
| سنة النشر: | 2018 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| مصطلحات موضوعية: | Aneurysmal bone cyst, bone tumor, denosumab, receptor activator of nuclear factor-kappa B ligand, Adolescent, Adult, Bone Cysts, Aneurysmal, Bone Density Conservation Agent, Female, Follow-Up Studie, Human, Male, Retrospective Studie, Treatment Outcome, Young Adult, Medicine (all) |
| الوصف: | PURPOSE:: Aneurysmal bone cyst (ABC) is a rare skeletal tumor usually treated with surgery/embolization. We hypothesized that owing to similarities with giant cell tumor of bone (GCTB), denosumab was active also in ABC. METHODS:: In this observational study, a retrospective analysis of ABC patients treated with denosumab was performed. Patients underwent radiologic disease assessment every 3 months. Symptoms and adverse events were noted. RESULTS:: Nine patients were identified (6 male, 3 female), with a median age of 17 years (range 14-42 years). Primary sites were 6 spine-pelvis, 1 ulna, 1 tibia, and 1 humerus. Patients were followed for a median time of 23 months (range 3-55 months). Patients received a median of 8 denosumab administrations (range 3-61). All symptomatic patients had pain relief and 1 had paresthesia improvement. Signs of denosumab activity were observed after 3 to 6 months of administration: bone formation by computed tomography scan was demonstrated in all patients and magnetic resonance imaging gadolinium contrast media decrease was observed in 7/9 patients. Adverse events were negligible. At last follow-up, all patients were progression-free: 5 still on denosumab treatment, 2 off denosumab were disease-free 11 and 17 months after surgery, and the last 2 patients reported no progression 12 and 24 months after denosumab interruption and no surgery. CONCLUSIONS:: Denosumab has substantial activity in ABCs, with favorable toxicity profile. We strongly support the use of surgery and/or embolization for the treatment of ABC, but denosumab could have a role as a therapeutic option in patients with uncontrollable, locally destructive, or recurrent disease. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/30086700; info:eu-repo/semantics/altIdentifier/wos/WOS:000452608900005; volume:104; issue:5; firstpage:344; lastpage:351; numberofpages:8; journal:TUMORI; http://hdl.handle.net/11568/939432Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85056588917 |
| DOI: | 10.1177/0300891618784808 |
| الإتاحة: | https://doi.org/10.1177/0300891618784808Test http://hdl.handle.net/11568/939432Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F88B08B4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1177/0300891618784808 |
|---|